Latest Conference Articles

Educated Patient® Kidney Cancer Summit Frontline Therapy Panel: April 9, 2022

Educated Patient® Kidney Cancer Summit Frontline Therapy Panel: April 9, 2022

April 24th 2022, 2:00pm

Educated Patient® Kidney Cancer Summit: April 9, 2022

Watch Dr. Thomas Hutson, Dr. Jose Karam, Dr, Naomi Haas, and Kiran Kehoe answer questions about frontline therapy during the CURE Educated Patient Kidney Cancer Summit.

Educated Patient® Kidney Cancer Summit Adjuvant Therapy Options Presentation: April 9, 2022

Educated Patient® Kidney Cancer Summit Adjuvant Therapy Options Presentation: April 9, 2022

April 23rd 2022, 2:00pm

Educated Patient® Kidney Cancer Summit: April 9, 2022

Watch Dr. Naomi Haas, from Abramson Cancer Center, discuss adjuvant therapy options, during the CURE Educated Patient Kidney Cancer Summit.

Educated Patient® Kidney Cancer Summit Surgical Options Presentation: April 9, 2022

Educated Patient® Kidney Cancer Summit Surgical Options Presentation: April 9, 2022

April 22nd 2022, 1:00pm

Educated Patient® Kidney Cancer Summit: April 9, 2022

Watch Dr. Jose Karam, from The University of Texas MD Anderson Cancer Center, discuss surgical options, during the CURE Educated Patient Kidney Cancer Summit.

Educated Patient® Kidney Cancer Summit Diagnosis Panel: April 9, 2022

Educated Patient® Kidney Cancer Summit Diagnosis Panel: April 9, 2022

April 21st 2022, 1:00pm

Watch Dr. Vitaly Margulis, Dr. Rana Mckay and Kwame Garrett-Price answer questions about kidney cancer diagnoses during the CURE Educated Patient Kidney Cancer Summit.

Educated Patient® Kidney Cancer Summit Genetic Testing in RCC Presentation: April 9, 2022

Educated Patient® Kidney Cancer Summit Genetic Testing in RCC Presentation: April 9, 2022

April 20th 2022, 1:00pm

Educated Patient® Kidney Cancer Summit: April 9, 2022

Watch Dr. Rana R. McKay, from the University of California San Diego, discuss genetic testing in renal cell carcinoma during the CURE Educated Patient Kidney Cancer Summit.

Educated Patient® Kidney Cancer Summit Staging Presentation: April 9, 2022

Educated Patient® Kidney Cancer Summit Staging Presentation: April 9, 2022

April 19th 2022, 1:00pm

Educated Patient® Kidney Cancer Summit: April 9, 2022

Watch Dr. Vitaly Margulis, from UT Southwestern Medical Center, discuss staging, during the CURE Educated Patient Kidney Cancer Summit.

Educated Patient® Multiple Myeloma Summit New Therapies on the Horizon Panel: March 12, 2022

Educated Patient® Multiple Myeloma Summit New Therapies on the Horizon Panel: March 12, 2022

April 9th 2022, 2:00pm

Educated Patient® Multiple Myeloma Summit: March 12, 2022

Watch Kristie L. Kahl, with Sham Mailankody, MBBS; Cesar Rodriguez, MD; and Lynn Steele, discuss new therapies on the horizon, during the CURE Educated Patient Multiple Myeloma Summit.

Educated Patient® Multiple Myeloma Summit Upcoming FDA Approvals Presentation: March 12, 2022

Educated Patient® Multiple Myeloma Summit Upcoming FDA Approvals Presentation: March 12, 2022

April 8th 2022, 1:00pm

Educated Patient® Multiple Myeloma Summit: March 12, 2022

Watch Dr. Cesar Rodriguez, of the Multiple Myeloma Program at the Ichan School of Medicine at Mount Sinai, discuss upcoming FDA approvals in the space, during the CURE Educated Patient Multiple Myeloma Summit.

Educated Patient® Multiple Myeloma Summit CAR/BiTE Presentation: March 12, 2022

Educated Patient® Multiple Myeloma Summit CAR/BiTE Presentation: March 12, 2022

April 7th 2022, 1:00pm

Educated Patient® Multiple Myeloma Summit: March 12, 2022

Watch Dr. Sham Mailankody, from Memorial Sloan Kettering Cancer Center, discuss CAR and BiTE therapy, during the CURE Educated Patient Multiple Myeloma Summit.

Educated Patient® Multiple Myeloma Summit MM4MM Keynote Lecture: March 12, 2022

Educated Patient® Multiple Myeloma Summit MM4MM Keynote Lecture: March 12, 2022

April 6th 2022, 1:00pm

Educated Patient® Multiple Myeloma Summit: March 12, 2022

Watch Dr. Saad Z. Usmani, Dr. Ben Marcus and Stan Wagner discuss their participation in the Moving Mountains for Multiple Myeloma program, during the CURE Educated Patient Multiple Myeloma Summit.

Educated Patient® Multiple Myeloma Summit Myeloma Treating Myeloma Long-Term Panel: March 12, 2022

Educated Patient® Multiple Myeloma Summit Myeloma Treating Myeloma Long-Term Panel: March 12, 2022

April 5th 2022, 1:00pm

Educated Patient® Multiple Myeloma Summit: March 12, 2022

Watch Kristie L. Kahl, Donna and Jack McNutt, Dr. Noopur Raje, and Grace Allison, discuss treating myeloma long term, during the CURE Educated Patient Multiple Myeloma Summit.

Educated Patient® Multiple Myeloma Summit Myeloma Treatment Panel: March 12, 2022

Educated Patient® Multiple Myeloma Summit Myeloma Treatment Panel: March 12, 2022

April 4th 2022, 1:00pm

Educated Patient® Multiple Myeloma Summit: March 12, 2022

Watch Dr. Saad Z. Usmani, Dr. Krina K. Patel, Dr. Noa Biran, and Jenny Ahlstrom, answer audience Q&A during the CURE Educated Patient Multiple Myeloma Summit.

Educated Patient® Multiple Myeloma Summit Relapsed/Refractory Myeloma Presentation: March 12, 2022

Educated Patient® Multiple Myeloma Summit Relapsed/Refractory Myeloma Presentation: March 12, 2022

April 3rd 2022, 2:00pm

Educated Patient® Multiple Myeloma Summit: March 12, 2022

Watch Dr. Noa Biran, an associate professor of medicine in the division of multiple myeloma at The John Theurer Cancer Center at Hackensack University Medical Center, discuss treatment for relapsed/refractory myeloma.

Educated Patient® Multiple Myeloma Summit Newly Diagnosed Myeloma Presentation: March 12, 2022

Educated Patient® Multiple Myeloma Summit Newly Diagnosed Myeloma Presentation: March 12, 2022

April 2nd 2022, 2:00pm

Educated Patient® Multiple Myeloma Summit: March 12, 2022

Watch Dr. Krina K. Patel, an associate professor and center medical director for the Department of Lymphoma-Myeloma at The University of Texas MD Anderson Cancer Center discuss treatment for newly diagnosed myeloma.

Educated Patient® Multiple Myeloma Summit Basics of Myeloma Panel: March 12, 2022

Educated Patient® Multiple Myeloma Summit Basics of Myeloma Panel: March 12, 2022

April 1st 2022, 1:00pm

Educated Patient® Multiple Myeloma Summit: March 12, 2022

Watch Saad Z. Usmani, MD, MBA, with Carlyn Rose Tan, MD; Neha S. Korde, MD; and Kenny Capps answer audience Q&A during the CURE Educated Patient Multiple Myeloma Summit.

Educated Patient® Multiple Myeloma Summit Risk Stratification for the Newly Diagnosed Presentation: March 12, 2022

Educated Patient® Multiple Myeloma Summit Risk Stratification for the Newly Diagnosed Presentation: March 12, 2022

March 31st 2022, 1:00pm

Educated Patient® Multiple Myeloma Summit: March 12, 2022

Watch Dr. Carlyn Rose Tan, an assistant attending in myeloma service at Memorial Sloan Kettering Cancer Center, present on risk stratification for newly diagnosed patients.

Educated Patient® Multiple Myeloma Summit MGUS/Smoldering Myeloma Presentation: March 12, 2022

Educated Patient® Multiple Myeloma Summit MGUS/Smoldering Myeloma Presentation: March 12, 2022

March 30th 2022, 1:00pm

Educated Patient® Multiple Myeloma Summit: March 12, 2022

Watch Dr. Neha S. Korde, an assistant professor in multiple myeloma service in the Division of Hematology at Memorial Sloan Kettering Cancer Center, present on MGUS/smoldering myeloma.

Intravenous and Direct-to-Abdomen Chemotherapy Plus Avastin Lead to Similar Outcomes in Advanced Ovarian Cancer

Intravenous and Direct-to-Abdomen Chemotherapy Plus Avastin Lead to Similar Outcomes in Advanced Ovarian Cancer

March 23rd 2022, 7:00pm

SGO Annual Meeting on Women's Cancer

There were no major differences in survival when comparing intravenous and intraperitoneal chemotherapy plus Avastin in patients with advanced ovarian cancer, research shows.

Treatment With Novel Drug Induces Promising Response Rates in Ovarian Cancer Subgroup

Treatment With Novel Drug Induces Promising Response Rates in Ovarian Cancer Subgroup

March 22nd 2022, 3:00pm

SGO Annual Meeting on Women's Cancer

“These results position mirvetuximab soravtansine to become a practice-changing, biomarker-driven, standard-of-care treatment option for patients with (high folate receptor-alpha)-positive, platinum-resistant ovarian cancer,” noted one of the study authors.

Zejula-Avastin Combo Improves Outcomes, With ‘No Impact on Quality of Life’ in High-Risk Ovarian Cancer

Zejula-Avastin Combo Improves Outcomes, With ‘No Impact on Quality of Life’ in High-Risk Ovarian Cancer

March 22nd 2022, 12:30pm

SGO Annual Meeting on Women's Cancer

Zejula plus Avastin led to promising progression-free survival rates with no new side effects for patients with newly diagnosed, advanced ovarian cancer.

PSMA-Targeted Treatment Improves Bone-Related Pain in Metastatic, Castration-Resistant Prostate Cancer

PSMA-Targeted Treatment Improves Bone-Related Pain in Metastatic, Castration-Resistant Prostate Cancer

March 7th 2022, 4:00pm

ASCO Genitourinary Symposium

Patients treated with Lutetium-177 PSMA-617 tended to experience improvements in quality of life related to the aches and pains that can come from bone metastases.

Drug Duo Sparks Encouraging Outcomes in Treatment of Clear Cell Kidney Cancer

Drug Duo Sparks Encouraging Outcomes in Treatment of Clear Cell Kidney Cancer

March 1st 2022, 10:00pm

In a recent clinical trial, treatment with Bavencio plus Inlyta produced promising outcomes in the presurgical treatment of patients with non-metastatic, clear cell renal cell carcinoma.

Cabometyx Before Surgery May Shrink Tumors With No Disease Progression in Advanced Kidney Cancer

Cabometyx Before Surgery May Shrink Tumors With No Disease Progression in Advanced Kidney Cancer

February 22nd 2022, 8:00pm

Treatment with Cabometyx before surgery in patients with advanced renal cell carcinoma, a type of kidney cancer, may provide benefits, although further research is required before a decision is made about its role in presurgical treatment.

Updated Results on Lenvima-Keytruda Combo ‘Still Encouraging’ for Patients With Advanced Kidney Cancer, Expert Says

Updated Results on Lenvima-Keytruda Combo ‘Still Encouraging’ for Patients With Advanced Kidney Cancer, Expert Says

February 22nd 2022, 4:41pm

ASCO Genitourinary Symposium

Although the data failed to identify a predictive biomarker in patients with advanced kidney cancer, an expert from Memorial Sloan Kettering Cancer Center in New York notes that the results indicate that no one should be excluded from receiving Lenvima plus Keytruda.

Immunotherapy Agent Misses Study Survival Goal in Advanced Penile Cancer

Immunotherapy Agent Misses Study Survival Goal in Advanced Penile Cancer

February 22nd 2022, 2:08pm

ASCO Genitourinary Symposium

Tecentriq failed to meet the progression-free survival goal in a trial analyzing the immunotherapy agent in advanced squamous cell carcinoma of the penis.

Even in the Prescence of Health Complications and Other Medications, Nubeqa Maintains Safety, Efficacy in Prostate Cancer Treatment

Even in the Prescence of Health Complications and Other Medications, Nubeqa Maintains Safety, Efficacy in Prostate Cancer Treatment

February 21st 2022, 8:00pm

ASCO Genitourinary Symposium

Patients with nonmetastatic castration-resistant prostate cancer who were taking other medications or had health complications still derived a survival benefit from treatment with Nubeqa, research showed.

Fotivda Boosts Survival and Has ‘Interesting’ – and Tolerable – Safety Profile for Kidney Cancer Treatment

Fotivda Boosts Survival and Has ‘Interesting’ – and Tolerable – Safety Profile for Kidney Cancer Treatment

February 21st 2022, 4:00pm

ASCO Genitourinary Symposium

Fotivda – a TKI drug that was approved last year – not only improved survival outcomes, but was also very tolerable in terms of side effects for patients with metastatic renal cell carcinoma.

Prehab, Rehab May Improve Health and Well-Being in Patients Receiving CAR-T Cell Therapy

Prehab, Rehab May Improve Health and Well-Being in Patients Receiving CAR-T Cell Therapy

February 15th 2022, 8:00pm

Prehab and rehab may help patients with cancer who are receiving CAR-T cell therapy return to health or even better, but there are still challenges.

Three-Drug Combo Proves Efficacious, Safe in Unresectable Liver Cancer

Three-Drug Combo Proves Efficacious, Safe in Unresectable Liver Cancer

February 7th 2022, 4:38pm

Treatment with a combination of PD-1 inhibition, minimally invasive chemotherapy and Lenvima improved outcomes for patients with unresectable liver cancer compared to PD-1 inhibition and Lenvima alone.

New Drug Combination May Improve Outcomes in Unresectable Liver Cancer

New Drug Combination May Improve Outcomes in Unresectable Liver Cancer

January 27th 2022, 10:00pm

ASCO Gastrointestinal Cancers Symposium

An expert from Memorial Sloan Kettering Cancer Center in New York discusses the promising findings from a study that analyzed tremelimumab plus Imfinzi for unresectable hepatocellular carcinoma, and outlines side effects patients should discuss with their doctor.